MGX

MKT CAP:$56M

Metagenomi, Inc. Common Stock

Market Cap

$56M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.43-$0.24 (-14.37%)

Apr 23, 2026

Company Details

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base ed...

CEO

Jian Irish

IPO Date

Apr 6, 2006

Website

www.metagenomi.co

Key Metrics TTM

Revenue

$25M

-51.8% YoY

Net Income

-$88M

EPS (Diluted)

-$2.37

Free Cash Flow

-$89M

Revenue / Share

$0.67

Gross Margin

0.3%

Operating Margin

-380.9%

Net Margin

-348.5%

FCF Margin

-354.9%

P/S

2.2x

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 5, 2026

$25M-51.8%EPS -$2.36

Q4 2025

Mar 5, 2026

$4M-59.3%EPS -$0.60

Q3 2025

Nov 12, 2025

$9M-24.8%EPS -$0.55

Q2 2025

Aug 12, 2025

$9M-57.5%EPS -$0.54

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$3M	-$5M	-$9M
Q2 22	$3M	-$5M	-$9M
Q3 22	$5M	$4M	-$11M
Q4 22	$6M	$5M	-$16M
Q1 23	$9M	-$11M	-$18M
Q2 23	$11M	-$11M	-$18M
Q3 23	$12M	-$14M	-$22M
Q4 23	$12M	-$12M	-$20M
Q1 24	$11M	-$20M	-$29M
Q2 24	$20M	$20M	-$17M
Q3 24	$12M	$12M	-$22M
Q4 24	$10M	$10M	-$21M
Q1 25	$4M	$4M	-$28M
Q2 25	$9M	-$14M	-$21M
Q3 25	$9M	$7M	-$23M
Q4 25	$4M	$3M	-$24M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	3.2x	—
Q1 23	2.5x	—
Q2 23	1.8x	—
Q3 23	1.5x	—
Q4 23	1.2x	—
Q1 24	1.2x	—
Q2 24	1.0x	—
Q3 24	1.0x	—
Q4 24	1.1x	—
Q1 25	1.2x	—
Q2 25	1.7x	—
Q3 25	1.8x	—
Q4 25	2.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$12M	-$15M
Q2 22	-$12M	-$15M
Q3 22	-$15M	-$18M
Q4 22	$68M	$64M
Q1 23	-$21M	-$24M
Q2 23	-$26M	-$29M
Q3 23	-$24M	-$26M
Q4 23	-$21M	-$22M
Q1 24	-$30M	-$31M
Q2 24	-$26M	-$27M
Q3 24	-$27M	-$28M
Q4 24	-$26M	-$27M
Q1 25	-$23M	-$23M
Q2 25	-$21M	-$21M
Q3 25	-$21M	-$21M
Q4 25	-$24M	-$24M

Capital Expenditures

Quarter	CapEx
Q1 22	$4M
Q2 22	$4M
Q3 22	$3M
Q4 22	$4M
Q1 23	$3M
Q2 23	$3M
Q3 23	$2M
Q4 23	$2M
Q1 24	$915.0K
Q2 24	$665.0K
Q3 24	$1M
Q4 24	$334.0K
Q1 25	$288.0K
Q2 25	$127.0K
Q3 25	$74.0K
Q4 25	$85.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+158.7%	+115.4%
Q2 23	+238.8%	+137.4%
Q3 23	+151.6%	+120.1%
Q4 23	+121.6%	+52.6%
Q1 24	+28.9%	+51.1%
Q2 24	+76.5%	+25.8%
Q3 24	-6.9%	-2.5%
Q4 24	-22.5%	-7.2%
Q1 25	-63.0%	-20.5%
Q2 25	-57.5%	-20.0%
Q3 25	-24.8%	-7.1%
Q4 25	-59.3%	-6.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$448.0K	13.4%
Q2 22	$448.0K	13.4%
Q3 22	$495.0K	10.1%
Q4 22	$571.0K	10.2%
Q1 23	$529.0K	6.1%
Q2 23	$656.0K	5.8%
Q3 23	$3M	26.4%
Q4 23	$2M	19.9%
Q1 24	$5M	45.3%
Q2 24	$5M	22.6%
Q3 24	$3M	28.0%
Q4 24	$3M	35.5%
Q1 25	$3M	70.9%
Q2 25	$3M	37.8%
Q3 25	$3M	34.8%
Q4 25	$3M	68.9%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$8M	$4M	—
Q2 22	$8M	$4M	—
Q3 22	$11M	$5M	—
Q4 22	$15M	$6M	—
Q1 23	$20M	$6M	—
Q2 23	$23M	$7M	—
Q3 23	$27M	$8M	—
Q4 23	$25M	$8M	—
Q1 24	$31M	$9M	—
Q2 24	$28M	$9M	—
Q3 24	$26M	$8M	—
Q4 24	$23M	$7M	—
Q1 25	$25M	$7M	—
Q2 25	$23M	$7M	—
Q3 25	$24M	$6M	—
Q4 25	$22M	—	$5M

Revenue Segments

Quarter	Operating Segments
Q1 25	$4M
Q2 25	$9M
Q3 25	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$0	$0	$0
Q4 22	$184M	$178M	$362M
Q1 23	$0	$0	$0
Q2 23	$52M	$267M	$318M
Q3 23	$102M	$191M	$293M
Q4 23	$141M	$131M	$271M
Q1 24	$103M	$225M	$327M
Q2 24	$61M	$239M	$300M
Q3 24	$25M	$249M	$275M
Q4 24	$27M	$221M	$248M
Q1 25	$29M	$197M	$226M
Q2 25	$27M	$178M	$205M
Q3 25	$33M	$151M	$184M
Q4 25	$42M	$119M	$161M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	6M	—	—
Q2 22	6M	0.0%	—
Q3 22	37M	+531.9%	—
Q4 22	37M	0.0%	—
Q1 23	30M	-20.0%	+405.3%
Q2 23	37M	+25.0%	+531.9%
Q3 23	37M	+0.0%	0.0%
Q4 23	37M	0.0%	0.0%
Q1 24	37M	-0.0%	+25.0%
Q2 24	37M	-0.0%	-0.0%
Q3 24	37M	-1.9%	-1.9%
Q4 24	37M	+0.9%	-1.0%
Q1 25	37M	-0.2%	-1.2%
Q2 25	37M	+0.4%	-0.8%
Q3 25	37M	+0.5%	+1.6%
Q4 25	38M	+0.7%	+1.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$52.5K	236
Q1 24	$47.3K	236
Q2 24	$84.8K	236
Q3 24	$48.8K	236
Q4 24	$47.6K	202
Q1 25	$20.4K	202
Q2 25	$42.1K	202
Q3 25	$42.9K	202
Q4 25	$20	200K

Revenue / Employee